Avaí Bio Hits Key Milestone: Klotho-Producing Cells Successfully Encapsulated and Secreting
AVAI sits 24% above its 52-week low of $0.101 on light trading volume (0.1× avg).
Summary
Avaí Bio and Austrianova have successfully encapsulated GMP-quality Klotho-producing cells in Cell-in-a-Box capsules, with initial studies showing robust Klotho secretion. This is the first confirmation that the cells remain viable and functional after encapsulation, a critical technical milestone for the joint venture's Klotho cell therapy program. The achievement follows the recent establishment of the Working Cell Bank and completion of viral testing on the Master Cell Bank. The program now advances to capsule expansion and optimization studies, which will evaluate long-term functionality and production performance. For a company with no revenue and a going concern warning, this technical validation is a meaningful step toward a viable therapeutic platform, though significant development and funding hurdles remain.
At the time of this announcement, AVAI was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.4M. The 52-week trading range was $0.10 to $0.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.